- Home
- NLOP vs KROS Comparison
NLOP vs KROS Comparison
Compare NLOP & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLOP
- KROS
- Stock Information
- Founded
- NLOP N/A
- KROS 2015
- Country
- NLOP United States
- KROS United States
- Employees
- NLOP N/A
- KROS N/A
- Industry
- NLOP
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- NLOP
- KROS Health Care
- Exchange
- NLOP Nasdaq
- KROS Nasdaq
- Market Cap
- NLOP 498.8M
- KROS 565.0M
- IPO Year
- NLOP N/A
- KROS 2020
- Fundamental
- Price
- NLOP $29.18
- KROS $16.29
- Analyst Decision
- NLOP Strong Buy
- KROS Buy
- Analyst Count
- NLOP 1
- KROS 14
- Target Price
- NLOP $46.00
- KROS $20.56
- AVG Volume (30 Days)
- NLOP 90.5K
- KROS 401.8K
- Earning Date
- NLOP 11-19-2025
- KROS 11-05-2025
- Dividend Yield
- NLOP 10.56%
- KROS N/A
- EPS Growth
- NLOP N/A
- KROS N/A
- EPS
- NLOP N/A
- KROS 0.47
- Revenue
- NLOP $117,598,000.00
- KROS $232,844,000.00
- Revenue This Year
- NLOP N/A
- KROS $6,657.47
- Revenue Next Year
- NLOP N/A
- KROS N/A
- P/E Ratio
- NLOP N/A
- KROS $34.64
- Revenue Growth
- NLOP N/A
- KROS 85820.30
- 52 Week Low
- NLOP $26.10
- KROS $9.12
- 52 Week High
- NLOP $34.53
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- NLOP 41.29
- KROS 59.90
- Support Level
- NLOP $29.00
- KROS $15.50
- Resistance Level
- NLOP $29.96
- KROS $16.57
- Average True Range (ATR)
- NLOP 0.48
- KROS 0.56
- MACD
- NLOP 0.08
- KROS -0.01
- Stochastic Oscillator
- NLOP 22.22
- KROS 81.53
About NLOP Net Lease Office Properties of Beneficial Interest
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.